Opko Bundle
Who Really Owns Opko Health?
Unraveling the Opko SWOT Analysis is just the beginning. Understanding the Opko Company's ownership structure is crucial for any investor or strategist. The Opko ownership landscape is a dynamic factor that shapes its strategic direction and market performance. Discover the key players behind this healthcare innovator and how their influence impacts its future.
From its inception in 1991, Opko Health has navigated the complex healthcare terrain, and its ownership has evolved significantly. Examining the company's ownership structure provides critical insights into its governance, strategic decisions, and overall potential. Whether you're tracking Opko stock, analyzing the Opko investors, or simply curious about Who founded Opko, this exploration will illuminate the forces driving Opko Health forward.
Who Founded Opko?
The story of Opko Health begins with its founder, Dr. Phillip Frost, a key figure in the healthcare industry. Founded in 1991, the company's early ownership structure was significantly shaped by Dr. Frost's initial investment and leadership.
Dr. Frost, serving as Chairman and CEO, has been central to Opko Company's growth. While precise details about the original founding team's equity distribution aren't readily available, Dr. Frost's influence has been consistently prominent. His early investment played a crucial role in establishing the company's financial foundation.
Early investment by Dr. Frost's group, The Frost Group, LLC, in 2007, further solidified the ownership structure. This investment provided a significant capital injection, which was critical for the company's early growth and development. The early ownership reflected the founders' vision and commitment to the company's future.
Founding
Founded in 1991 by Dr. Phillip Frost.
Early Investment
The Frost Group, LLC, invested $20 million on December 4, 2007.
Share Issuance
Issued 10,869,565 shares at $1.84 per share in 2007.
Ownership Stake
The Frost Group held approximately 55.2% of the outstanding shares after the 2007 investment.
Lockup Period
Shares held by the Frost Group were subject to a two-year lockup period.
Key Figures
Key figures included Dr. Phillip Frost, Dr. Jane Hsiao, Dr. Rao Uppaluri, and Mr. Steven D. Rubin.
Key Takeaways
The early ownership of Opko ownership was heavily influenced by Dr. Phillip Frost, the founder. His investments and leadership were crucial in the initial stages of the company. The Frost Group's investment in 2007 significantly increased their stake, demonstrating a strong commitment to the company's long-term vision. This concentrated ownership structure, established early on, provided a solid foundation for the company's future development and strategic direction.
- Dr. Phillip Frost founded Opko Health in 1991 and remains a key figure.
- The Frost Group's investment in 2007 was a significant event in the company's history.
- The early ownership structure was concentrated, with Dr. Frost and his group holding a majority stake.
- The lockup period ensured stability among the major shareholders.
Opko SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Opko’s Ownership Changed Over Time?
The ownership structure of Opko Health, a publicly traded company on the NASDAQ under the ticker symbol OPK, has evolved significantly since its founding. As of June 2025, the company's market capitalization is approximately $1.07 billion USD, with roughly 793 million shares outstanding as of June 13, 2025. This structure reflects a mix of institutional, insider, and retail investors, each playing a role in the company's financial landscape. The company's journey has been marked by strategic shifts that have influenced its ownership composition.
Key events impacting the ownership structure include the sale of BioReference Health's oncology and related clinical testing businesses to Labcorp, with a definitive agreement signed in March 2025. This transaction, along with a similar sale in September 2024, is designed to streamline operations and could generate up to $462.5 million to support business expansion and debt reduction. Additionally, the collaboration with Entera Bio in March 2025 to develop an oral GLP-1/glucagon tablet for obesity, where Opko Health holds a 60% ownership interest, is another significant development.
| Stakeholder | Approximate Ownership (May 2025) | Notes |
|---|---|---|
| Institutional Investors | Approximately 31.02% | Includes Rubric Capital Management LP, Vanguard Group Inc, and BlackRock, Inc. |
| Insiders | 6.18% | Includes Dr. Phillip Frost, a significant individual shareholder. |
| Retail Investors | Approximately 28.75% | Represents individual investors. |
Major stakeholders in Opko Company include institutional investors, mutual funds, individual investors, and company insiders. As of May 2025, institutional investors hold approximately 31.02% of the company's stock, while insiders hold 6.18%, and retail investors account for about 28.75%. Dr. Phillip Frost remains a significant individual shareholder, with sole voting and dispositive power over 249,330,142 shares as of February 24, 2025. His consistent share purchases, exceeding $9 million between September 2024 and April 2025, demonstrate strong confidence in the company's direction. For more detailed information, you can read a comprehensive analysis of the company's performance and future prospects.
Key Takeaways on Opko Ownership
Opko Health's ownership is diversified, with institutional investors holding a significant portion of the stock.
- Dr. Phillip Frost is a key insider, demonstrating confidence through consistent share purchases.
- Recent strategic moves, like the sale of BioReference Health assets, are reshaping the company's financial landscape.
- The collaboration with Entera Bio adds another layer to Opko's business portfolio.
- Understanding the Opko ownership structure is crucial for investors.
Opko PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Opko’s Board?
The current Board of Directors of Opko Health plays a vital role in the company's governance. As of 2024, Dr. Phillip Frost holds the positions of both Chairman and CEO. Other key figures include Elias Zerhouni, who is the Co-Founder of ModeX Therapeutics and President and Vice Chairman of the Board of Directors for Opko Health, and Dr. Gary Nabel, Co-Founder, President, and CEO of ModeX Therapeutics, as well as Chief Innovation Officer and a Board Director for Opko Health.
The composition of the board includes individuals with diverse backgrounds, including major shareholders and independent directors. This structure aims to ensure a balance of interests and perspectives in the decision-making processes. The board's responsibilities encompass overseeing the company's strategic direction, financial performance, and overall operations, ensuring accountability to shareholders and stakeholders.
| Board Member | Title | Affiliation |
|---|---|---|
| Dr. Phillip Frost | Chairman and CEO | Opko Health |
| Elias Zerhouni | President and Vice Chairman of the Board | ModeX Therapeutics, Opko Health |
| Dr. Gary Nabel | Chief Innovation Officer and Board Director | ModeX Therapeutics, Opko Health |
Regarding voting rights, holders of Opko Health's common stock are entitled to one vote per share on all matters submitted to stockholders. As of February 24, 2025, Dr. Phillip Frost, through Frost Gamma Investments Trust, held significant voting power, with sole voting and dispositive power over 249,330,142 shares of the company's common stock. This substantial ownership gives Dr. Frost considerable influence over company decisions. The company's proxy statement for the 2025 Annual Meeting of Stockholders, held on April 23, 2025, included items such as the election of the Board's nominees, the Say on Pay proposal, and the ratification of Ernst & Young, LLP as the independent registered public accounting firm for fiscal year 2025. Shareholders could participate and submit questions online during the annual meeting.
Key Takeaways on Opko Health Ownership
Understanding the board of directors and voting power is crucial for Opko investors.
- Dr. Phillip Frost holds significant influence as Chairman, CEO, and through substantial share ownership.
- Shareholders have voting rights, with key decisions made at the annual meetings.
- The board includes individuals from various backgrounds, including major shareholders.
- Knowing who founded Opko, and who are the major shareholders of Opko is key to understanding the company.
Opko Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Opko’s Ownership Landscape?
In recent years, Opko Health has actively managed its ownership structure through significant share repurchase programs and strategic financial maneuvers. In April 2025, the Board of Directors approved an additional $100 million for its common stock repurchase initiative, increasing the total capacity to $200 million. This follows the repurchase of approximately $40.2 million of common stock under the previous program, which began in July 2024. These actions reflect management's belief that the company's shares are undervalued.
Further restructuring efforts included repurchasing $17.0 million of principal convertible notes for $25.0 million and an additional 10.9 million common shares for $16.5 million during the fourth quarter of 2024. These moves led to an 81.0 million share reduction, or 10% of outstanding shares, in 2024. Post-Q1 2025, Opko completed an exchange agreement to acquire $159.2 million of outstanding convertible notes for 121.4 million shares and around $63.5 million in cash. Dr. Phillip Frost, Chairman and CEO, has demonstrated confidence in the company's future through consistent stock purchases, investing over $9 million between September 2024 and April 2025.
| Metric | Details | Date |
|---|---|---|
| Share Repurchase Program Authorization | Additional $100 million | April 2025 |
| Institutional Ownership | Remained at 31.02% | May 2025 |
| Mutual Fund Holdings | Increased from 13.45% to 14.00% | May 2025 |
These strategic financial actions and leadership decisions highlight a commitment to optimizing the company's capital structure and signaling confidence to Opko investors. The company's strong cash position of $449.7 million as of March 31, 2025, provides financial flexibility for ongoing share repurchases and pipeline development. The focus on streamlining operations, as seen in the sale of oncology assets, indicates a strategic shift towards core business areas.
Opko Health Stock
The company’s approach to stock buybacks and debt management influences the Opko stock performance, reflecting management's strategies to enhance shareholder value. These financial moves are designed to improve the company's financial standing and boost investor confidence.
Major Shareholders of Opko
The ownership structure, including institutional and mutual fund holdings, offers insights into the confidence level of major investors in the Opko Company. The stable institutional ownership and increasing mutual fund holdings reflect positive sentiment.
Who Founded Opko
Understanding the company's history and leadership, including the role of Dr. Phillip Frost, provides a comprehensive view of Who is the CEO of Opko Health and the company's strategic direction. His continued investment in the company underscores his commitment.
Opko Health Financials
The financial performance, including cash reserves and strategic divestitures, shapes the outlook for the Opko Health stock price today and future growth. The strong cash position supports future strategic initiatives and operational needs.
Opko Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Opko Company?
- What is Competitive Landscape of Opko Company?
- What is Growth Strategy and Future Prospects of Opko Company?
- How Does Opko Company Work?
- What is Sales and Marketing Strategy of Opko Company?
- What is Brief History of Opko Company?
- What is Customer Demographics and Target Market of Opko Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.